LifeVantage Corporation (NASDAQ:LFVN) reported its financial results for the second quarter of fiscal year 2024, surpassing analysts' expectations with an earnings per share (EPS) of $0.22 compared to ...

LifeVantage Corporation ( NASDAQ: LFVN) Q2 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Reed Anderson – Managing Director-ICR Steve Fife – President and Chief Executive Officer Carl Aure ...

Gross profit for the second quarter of fiscal 2025 was $54.6 million, or 80.5% of revenue, compared to $40.6 million, or 78.6 ...

CEO Steve Fife highlighted the success of the MindBody GLP-1 System, which drove Q2 revenue to $67.8 million, marking a sequential increase of 44% and a year-over-year growth of 31%. Active accounts ...

LifeVantage Corp. engages in the identification, research, development, formulation, and sale of nutraceutical dietary supplements and personal care products. Its products include Protandim, Axio ...

Fintel reports that on January 14, 2025, Craig-Hallum initiated coverage of LifeVantage (NasdaqCM:LFVN) with a Buy recommendation. Analyst Price Forecast Suggests 3.07% Upside As of December 23 ...

In such a dynamic environment, identifying promising small-cap stocks like LifeVantage can offer unique opportunities for investors seeking growth potential beyond well-trodden paths.

Detailed price information for Lifevantage Corp (LFVN-Q) from The Globe and Mail including charting and trades.

Lake Street analyst Brooks O’Neil initiated coverage of LifeVantage (LFVN) with a Buy rating and $26 price target The company’s products activate physical wellness by using science-based ...